Literature DB >> 17084612

Fragment-based lead discovery: a chemical update.

Daniel A Erlanson1.   

Abstract

Fragment-based lead discovery constructs drug leads from small molecular fragments. In theory, this is a highly efficient method for drug discovery, and the technique has become enormously popular in the past few years. In this review, I describe how a variety of approaches in fragment-based lead discovery--including NMR, X-ray crystallography, mass spectrometry, functional screening, and in silico screening--have produced drug leads. Although the examples show that the technique can reliably generate potent molecules, there is still much work to be done to maintain the efficiency of molecules' binding affinities as fragments are linked, expanded, and otherwise improved.

Mesh:

Substances:

Year:  2006        PMID: 17084612     DOI: 10.1016/j.copbio.2006.10.007

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  30 in total

Review 1.  Adenylating enzymes in Mycobacterium tuberculosis as drug targets.

Authors:  Benjamin P Duckworth; Kathryn M Nelson; Courtney C Aldrich
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

3.  Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4.

Authors:  Erik Evensen; Diane Joseph-McCarthy; Gregory A Weiss; Stuart L Schreiber; Martin Karplus
Journal:  J Comput Aided Mol Des       Date:  2007-07-27       Impact factor: 3.686

4.  Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.

Authors:  Hernani Leonardo Silvestre; Thomas L Blundell; Chris Abell; Alessio Ciulli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

5.  The multiple roles of computational chemistry in fragment-based drug design.

Authors:  Richard Law; Oliver Barker; John J Barker; Thomas Hesterkamp; Robert Godemann; Ole Andersen; Tara Fryatt; Steve Courtney; Dave Hallett; Mark Whittaker
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

6.  Drug discovery: A question of library design.

Authors:  Philip J Hajduk; Warren R J D Galloway; David R Spring
Journal:  Nature       Date:  2011-02-03       Impact factor: 49.962

7.  Fragment-based lead discovery: challenges and opportunities.

Authors:  Chaohong Sun; Andrew M Petros; Philip J Hajduk
Journal:  J Comput Aided Mol Des       Date:  2011-07-06       Impact factor: 3.686

Review 8.  Fragment-based approaches to enzyme inhibition.

Authors:  Alessio Ciulli; Chris Abell
Journal:  Curr Opin Biotechnol       Date:  2007-10-24       Impact factor: 9.740

9.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 10.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.